Tambe Moves Up To Lead Biocon Biologics
Replaces CEO Arun Chandavarkar, Who Will Continue To Serve As Director
Shreehas Tambe has been named as CEO of Biocon Biologics, taking over from Arun Chandavarkar, in the wake of the company’s milestone $3bn transaction for Viatris’s biosimilars business.
You may also be interested in...
Executive changes in 2022 reveal how the industry is adjusting to a volatile post-COVID environment.
Biocon has seen its insulin-R application knocked back by the US FDA, with a complete response letter citing a need for more data as well as the need for remediation activities at its Bangalore facilities.
Looking back over the fourth quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from October to December that include a leadership change for one of the top industry players, some key developments for biosimilars and the announcement of the winners of our annual awards.